GlassScriptPhysician profile
Jorge A Saravia
NPI 1629175625
$1,543.96
in general payments reported to CMS, 2019-2025
24 companies · $45.84 in 2025
The $45.84 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $530 · 2021: $148 · 2022: $185 · 2023: $126 · 2024: $60.58 · 2025: $45.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $339.20 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $164.88 | 2019-2023 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $140.15 | 2021-2022 | |
| Amgen INC. | $130.45 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $112.24 | 2019-2023 | Austedo |
| Amneal Pharmaceuticals LLC | $88.85 | 2019-2020 | |
| Medtronic, INC. | $73.38 | 2024-2025 | Percept PC Brainsense |
| Abbvie INC. | $55.82 | 2022-2025 | |
| Kyowa Kirin, INC. | $47.83 | 2019-2020 | |
| Mdd US Operations, LLC | $45.69 | 2019-2024 | Gocovri |
| Novartis Pharmaceuticals Corporation | $42.37 | 2019-2023 | |
| Adamas Pharmaceuticals, INC. | $39.34 | 2020 | |
| Ge Healthcare | $35.38 | 2019-2022 | |
| Sk Life Science, INC. | $33.80 | 2020 | |
| Eisai INC. | $24.98 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $23.43 | 2022 | |
| Greenwich Biosciences, INC. | $22.20 | 2020 | |
| Neurocrine Biosciences, INC. | $21.36 | 2020 | |
| Pfizer INC. | $20.05 | 2023 | |
| Emd Serono, INC. | $18.88 | 2019 | |
| Vanda Pharmaceuticals INC. | $18.46 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $17.50 | 2023 | Spritam |
| Medtronic USA, INC. | $16.47 | 2019 | |
| Validus Pharmaceuticals LLC | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Saravia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.